Thomas Shrader
Stock Analyst at BTIG
(3.31)
# 1,095
Out of 5,105 analysts
67
Total ratings
46.67%
Success rate
4.67%
Average return
Main Sectors:
Stocks Rated by Thomas Shrader
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DNLI Denali Therapeutics | Reiterates: Buy | $32 | $17.98 | +77.98% | 3 | Dec 5, 2025 | |
| NRXP NRx Pharmaceuticals | Reiterates: Buy | $25 | $2.07 | +1,107.73% | 1 | Dec 3, 2025 | |
| BHVN Biohaven | Reiterates: Buy | $16 | $11.53 | +38.77% | 5 | Nov 18, 2025 | |
| ANRO Alto Neuroscience | Initiates: Buy | $27 | $15.13 | +78.45% | 1 | Nov 17, 2025 | |
| COYA Coya Therapeutics | Maintains: Buy | $15 → $16 | $6.18 | +158.90% | 3 | Nov 13, 2025 | |
| PCVX Vaxcyte | Reiterates: Buy | $85 | $44.50 | +91.01% | 5 | Nov 10, 2025 | |
| ALDX Aldeyra Therapeutics | Reiterates: Buy | $9 | $4.54 | +98.24% | 2 | Nov 10, 2025 | |
| STOK Stoke Therapeutics | Reiterates: Buy | $39 | $32.39 | +20.41% | 2 | Nov 5, 2025 | |
| ACIU AC Immune | Reiterates: Buy | $8 | $3.15 | +153.97% | 3 | Nov 4, 2025 | |
| ARCT Arcturus Therapeutics Holdings | Maintains: Buy | $48 → $23 | $7.46 | +208.31% | 2 | Oct 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.49 | - | 4 | Oct 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $9 | $4.14 | +117.39% | 4 | Oct 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7 → $14 | $6.74 | +107.72% | 1 | Oct 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $63 | $47.06 | +33.87% | 3 | Sep 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $72 | $84.19 | -14.48% | 1 | Sep 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $2.01 | - | 3 | Jul 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $5 → $4 | $1.64 | +143.90% | 3 | Mar 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $3.92 | - | 3 | Sep 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $200 | $8.99 | +2,124.69% | 1 | Oct 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $180 → $60 | $4.99 | +1,102.40% | 1 | Jul 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15 → $7 | $4.97 | +40.85% | 2 | May 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $68 → $13 | $0.82 | +1,476.90% | 3 | Mar 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15 → $22 | $2.14 | +928.04% | 2 | Oct 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $51 | $1.23 | +4,046.34% | 1 | Apr 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16 | $8.43 | +89.80% | 1 | Mar 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $4.39 | - | 1 | Feb 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $4 → $3 | $1.36 | +120.59% | 3 | Apr 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $397 → $346 | $174.10 | +98.74% | 3 | Feb 21, 2019 |
Denali Therapeutics
Dec 5, 2025
Reiterates: Buy
Price Target: $32
Current: $17.98
Upside: +77.98%
NRx Pharmaceuticals
Dec 3, 2025
Reiterates: Buy
Price Target: $25
Current: $2.07
Upside: +1,107.73%
Biohaven
Nov 18, 2025
Reiterates: Buy
Price Target: $16
Current: $11.53
Upside: +38.77%
Alto Neuroscience
Nov 17, 2025
Initiates: Buy
Price Target: $27
Current: $15.13
Upside: +78.45%
Coya Therapeutics
Nov 13, 2025
Maintains: Buy
Price Target: $15 → $16
Current: $6.18
Upside: +158.90%
Vaxcyte
Nov 10, 2025
Reiterates: Buy
Price Target: $85
Current: $44.50
Upside: +91.01%
Aldeyra Therapeutics
Nov 10, 2025
Reiterates: Buy
Price Target: $9
Current: $4.54
Upside: +98.24%
Stoke Therapeutics
Nov 5, 2025
Reiterates: Buy
Price Target: $39
Current: $32.39
Upside: +20.41%
AC Immune
Nov 4, 2025
Reiterates: Buy
Price Target: $8
Current: $3.15
Upside: +153.97%
Arcturus Therapeutics Holdings
Oct 22, 2025
Maintains: Buy
Price Target: $48 → $23
Current: $7.46
Upside: +208.31%
Oct 22, 2025
Downgrades: Neutral
Price Target: n/a
Current: $1.49
Upside: -
Oct 15, 2025
Reiterates: Buy
Price Target: $9
Current: $4.14
Upside: +117.39%
Oct 13, 2025
Maintains: Buy
Price Target: $7 → $14
Current: $6.74
Upside: +107.72%
Sep 29, 2025
Reiterates: Buy
Price Target: $63
Current: $47.06
Upside: +33.87%
Sep 8, 2025
Initiates: Buy
Price Target: $72
Current: $84.19
Upside: -14.48%
Jul 1, 2025
Downgrades: Neutral
Price Target: n/a
Current: $2.01
Upside: -
Mar 24, 2025
Maintains: Buy
Price Target: $5 → $4
Current: $1.64
Upside: +143.90%
Sep 4, 2024
Downgrades: Neutral
Price Target: n/a
Current: $3.92
Upside: -
Oct 3, 2023
Initiates: Buy
Price Target: $200
Current: $8.99
Upside: +2,124.69%
Jul 28, 2023
Maintains: Buy
Price Target: $180 → $60
Current: $4.99
Upside: +1,102.40%
May 25, 2023
Maintains: Buy
Price Target: $15 → $7
Current: $4.97
Upside: +40.85%
Mar 28, 2023
Maintains: Buy
Price Target: $68 → $13
Current: $0.82
Upside: +1,476.90%
Oct 5, 2022
Maintains: Buy
Price Target: $15 → $22
Current: $2.14
Upside: +928.04%
Apr 20, 2021
Initiates: Buy
Price Target: $51
Current: $1.23
Upside: +4,046.34%
Mar 8, 2021
Initiates: Buy
Price Target: $16
Current: $8.43
Upside: +89.80%
Feb 3, 2021
Downgrades: Neutral
Price Target: n/a
Current: $4.39
Upside: -
Apr 3, 2020
Maintains: Buy
Price Target: $4 → $3
Current: $1.36
Upside: +120.59%
Feb 21, 2019
Downgrades: Hold
Price Target: $397 → $346
Current: $174.10
Upside: +98.74%